# DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

> **NCT03305471** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 40 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** DS-2330b PIB
- **DRUG:** Placebo
- **DRUG:** Sevelamer
- **DRUG:** DS-2330b Tablet

## Key facts

- **NCT ID:** NCT03305471
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2019-01-03
- **Final completion:** 2019-01-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03305471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03305471, "DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03305471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*